These data using biologically aggressive endometrial cancer models are consistent and extend the recent preclinically work from our group using these novel RAF/MEKi and FAKi against other difficult to treat gynecologic tumors (i.e., uterine carcinosarcomas) as well as the encouraging data recently presented in patient‐derived low‐grade serous ovarian cancer (LGSOC) using in vivo models treated with the combination avutometinib/defactinib.12, 33, 34. Here, RAF1 is linked to endometrial cancer.